FDA Approves Prescription Digital Therapeutic for Migraine Prevention
Tuesday, 22 April 2025, 06:24
FDA Approval of CT-132 for Migraine Prevention
The FDA has granted marketing authorization for CT-132, a prescription digital therapeutic aimed at preventing episodic migraines in patients aged 18 years and older.
Details of the Digital Therapeutic
- CT-132 aims to reduce the frequency of migraine attacks.
- It incorporates behavioral therapy and personalized approaches.
- This option is particularly advantageous for individuals who prefer digital solutions.
Implications for Migraine Treatment
This development underscores a growing trend in healthcare technology where digital tools are being utilized to manage chronic conditions effectively. Patients now have another tool in their arsenal to combat the debilitating effects of migraines.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.